{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:27:25Z","timestamp":1783686445082,"version":"3.55.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1111\/jth.15773","type":"journal-article","created":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T02:24:45Z","timestamp":1653791085000},"page":"1766-1777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["The role of VWF\/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0809-557X","authenticated-orcid":false,"given":"Claire","family":"Comerford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8601-2090","authenticated-orcid":false,"given":"Siobhan","family":"Glavey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6434-0846","authenticated-orcid":false,"given":"John","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1162-8739","authenticated-orcid":false,"given":"Jamie M.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1111\/jth.15773_bb0010","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1111\/jth.15773_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1055\/s-0041-1722863","article-title":"Advances in the management of cancer\u2010associated thrombosis","volume":"47","author":"Dhami","year":"2021","journal-title":"Semin Thromb Hemost"},{"key":"10.1111\/jth.15773_bb0020","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","article-title":"Prognosis of cancers associated with venous thromboembolism","volume":"343","author":"S\u00f8rensen","year":"2000","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1111\/jth.15773_bb0025","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer\u2010associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"02","key":"10.1111\/jth.15773_bb0030","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0037-1607352","article-title":"Emerging roles for von willebrand factor in cancer cell biology","volume":"44","author":"O'Sullivan","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"9","key":"10.1111\/jth.15773_bb0035","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"24","key":"10.1111\/jth.15773_bb0040","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1182\/blood-2009-11-252072","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population\u2010based study","volume":"115","author":"Kristinsson","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1111\/jth.15773_bb0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.17772","article-title":"Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib , lenalidomide , dexamethasone ( RVD ) or carfilzomib , lenalidomide , dexamethasone ( KRD ) with aspirin or rivaroxaban thromboprophylaxis","volume":"196","author":"Piedra","year":"2021","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1111\/jth.15773_bb0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-019-0784-4","article-title":"Cardiovascular complications associated with multiple myeloma therapies: incidence, pathophysiology, and management","volume":"21","author":"Patel","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1111\/jth.15773_bb0055","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15773_bb0060","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1111\/jth.14976","article-title":"Von Willebrand Factor and cancer; metastasis and coagulopathies","volume":"18","author":"Patmore","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1111\/jth.15773_bb0065","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1182\/blood-2014-08-595686","article-title":"Von Willebrand factor fibers promote cancer\u2010associated platelet aggregation in malignant melanoma of mice and humans","volume":"125","author":"Bauer","year":"2015","journal-title":"Blood"},{"issue":"15","key":"10.1111\/jth.15773_bb0070","doi-asserted-by":"crossref","first-page":"7766","DOI":"10.1158\/0008-5472.CAN-05-3897","article-title":"Tumor\u2010derived matrix metalloproteinase\u20101 targets endothelial proteinase\u2010activated receptor 1 promoting endothelial cell activation","volume":"66","author":"Goerge","year":"2006","journal-title":"Cancer Res"},{"issue":"2","key":"10.1111\/jth.15773_bb0075","first-page":"283","article-title":"Microfluidic reveals generation of platelet\u2010strings on tumor\u2010activated endothelium","volume":"98","author":"Goerge","year":"2007","journal-title":"Thromb Haemost"},{"issue":"9","key":"10.1111\/jth.15773_bb0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1111\/jth.15773_bb0085","doi-asserted-by":"crossref","first-page":"m3176","DOI":"10.1136\/bmj.m3176","article-title":"Emerging immunotherapies in multiple myeloma","volume":"370","author":"Shah","year":"2020","journal-title":"BMJ"},{"issue":"22","key":"10.1111\/jth.15773_bb0090","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1111\/jth.15773_bb0095","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/bjh.15684","article-title":"Venous thromboembolism in multiple myeloma \u2013 choice of prophylaxis, role of direct oral anticoagulants and special considerations","volume":"183","author":"Swan","year":"2018","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1111\/jth.15773_bb0100","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/ajh.25603","article-title":"Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score","volume":"94","author":"Sanfilippo","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1111\/jth.15773_bb0105","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2019-124403","article-title":"VTE rates and safety analysis of newly diagnosed multiple myeloma patients receiving carfilzomib\u2010lenalidomide\u2010dexamethasone (KRD) with or without rivaroxaban prophylaxis","volume":"134","author":"Piedra","year":"2019","journal-title":"Blood"},{"issue":"22","key":"10.1111\/jth.15773_bb0110","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1182\/blood.V114.22.1872.1872","article-title":"Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population\u2010based study","volume":"114","author":"Kristinsson","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1111\/jth.15773_bb0115","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1111\/jth.15773_bb0120","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/bjh.15392","article-title":"Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide\u2010 and lenalidomide\u2010containing regimens","volume":"185","author":"Storrar","year":"2019","journal-title":"Br J Haematol"},{"issue":"16","key":"10.1111\/jth.15773_bb0125","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/jcm10163536","article-title":"Validation of risk\u2010adapted venous thromboembolism prediction in multiple myeloma patients","volume":"10","author":"Barrett","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"10.1111\/jth.15773_bb0130","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"10.1111\/jth.15773_bb0135","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00432-021-03693-5","article-title":"Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real\u2010life study","volume":"148","author":"Leclerc","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1111\/jth.15773_bb0140","first-page":"214","article-title":"Potential mechanisms of resistance to current anti\u2010thrombotic strategies in Multiple Myeloma","volume":"5","author":"Comerford","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"12","key":"10.1111\/jth.15773_bb0145","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3109\/10428194.2015.1041385","article-title":"Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma","volume":"56","author":"Gracheva","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1111\/jth.15773_bb0150","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.15815","article-title":"Effect of heparin thromboprophylaxis on thrombin generation in multiple myeloma patients","volume":"186","author":"Chalayer","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1111\/jth.15773_bb0155","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1002\/onco.13569","article-title":"Prediction and prevention of cancer\u2010associated thromboembolism","volume":"26","author":"Khorana","year":"2021","journal-title":"Oncologist"},{"issue":"7","key":"10.1111\/jth.15773_bb0160","doi-asserted-by":"crossref","first-page":"840","DOI":"10.6004\/jnccn.2018.7273","article-title":"Derivation and validation of a risk assessment model for immunomodulatory drug\u2010associated thrombosis among patients with multiple myeloma","volume":"17","author":"Li","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1111\/jth.15773_bb0165","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S0049-3848(20)30401-1","article-title":"Assessing the risk of venous thromboembolism in multiple myeloma","volume":"191","author":"Sanfilippo","year":"2020","journal-title":"Thromb Res"},{"issue":"13","key":"10.1111\/jth.15773_bb0170","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","article-title":"von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends","volume":"125","author":"Lenting","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1111\/jth.15773_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1749-6632.1991.tb43700.x","article-title":"von Willebrand Factor biosynthesis and processing","volume":"614","author":"Mayadas","year":"1991","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1111\/jth.15773_bb0180","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jth.14343","article-title":"High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor","volume":"17","author":"Rietveld","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1111\/jth.15773_bb0185","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1111\/j.1538-7836.2006.02273.x","article-title":"von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis","volume":"4","author":"Nossent","year":"2006","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1111\/jth.15773_bb0190","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1146\/annurev-med-061813-013241","article-title":"ADAMTS13 and von Willebrand Factor in thrombotic thrombocytopenic purpura","volume":"66","author":"Long Zheng","year":"2015","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1111\/jth.15773_bb0195","first-page":"454","article-title":"Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS\u201013 (von Willebrand factor cleaving protease)","volume":"88","author":"Mannucci","year":"2003","journal-title":"Haematologica"},{"issue":"3","key":"10.1111\/jth.15773_bb0200","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/rth2.12197","article-title":"The role of ADAMTS\u201013 and von Willebrand factor in cancer patients: results from the Vienna cancer and thrombosis study","volume":"3","author":"Obermeier","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"10.1111\/jth.15773_bb0205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/jth.13205","article-title":"ADAMTS\u201013 and von Willebrand factor predict venous thromboembolism in patients with cancer","volume":"14","author":"P\u00e9pin","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.15773_bb0210","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/jth.15409","article-title":"ADAMTS13 regulation of VWF multimer distribution in severe COVID\u201019","volume":"19","author":"Ward","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"42","key":"10.1111\/jth.15773_bb0215","doi-asserted-by":"crossref","first-page":"68527","DOI":"10.18632\/oncotarget.11832","article-title":"Heparins that block VEGF\u2010A\u2010mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis","volume":"7","author":"Goertz","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1111\/jth.15773_bb0220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12876-019-1082-1","article-title":"VWF\/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma","volume":"19","author":"Takaya","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"Suppl 1","key":"10.1111\/jth.15773_bb0225","first-page":"1","article-title":"Dynamics of ADAMTS13 and vWF activity change in ovarian cancer patients [abstract]","volume":"4","author":"Vorobev","year":"2020","journal-title":"Res Pr Thromb Haemost"},{"issue":"5","key":"10.1111\/jth.15773_bb0230","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1007\/s12032-012-0290-0","article-title":"Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma","volume":"29","author":"Robak","year":"2012","journal-title":"Med Oncol"},{"issue":"2","key":"10.1111\/jth.15773_bb0235","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2141.1976.tb00928.x","article-title":"Factor VIII and Factor\u2010VIII\u2010related antigen in multiple myelomatosis and related conditions","volume":"32","author":"Gomperts","year":"1976","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1111\/jth.15773_bb0240","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1076029615625825","article-title":"Plasma thrombin generation and sensitivity to activated protein c among patients with myeloma and monoclonal gammopathy of undetermined significance","volume":"22","author":"Crowley","year":"2016","journal-title":"Clin Appl Thromb"},{"issue":"2","key":"10.1111\/jth.15773_bb0245","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.10454","article-title":"Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma","volume":"92","author":"Auwerda","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1111\/jth.15773_bb0250","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1111\/jth.15773_bb0255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","article-title":"Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications","volume":"13","author":"Zangari","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"10.1111\/jth.15773_bb0260","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-2143(96)90116-X","article-title":"Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma","volume":"128","author":"Carr","year":"1996","journal-title":"J Lab Clin Med"},{"issue":"15","key":"10.1111\/jth.15773_bb0265","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1200\/JCO.2010.32.8294","article-title":"Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: Results from the vienna cancer and thrombosis study","volume":"29","author":"Ay","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1111\/jth.15773_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2017.03.010","article-title":"Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients","volume":"65","author":"Leiba","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"10.1111\/jth.15773_bb0275","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-018-0135-y","article-title":"Longer procoagulant phospholipid\u2010dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results","volume":"8","author":"Fotiou","year":"2018","journal-title":"Blood Cancer J"},{"issue":"August","key":"10.1111\/jth.15773_bb0280","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2017.08.011","article-title":"Hypocoagulability as assessed by thrombin generation test in newly\u2010diagnosed patients with multiple myeloma","volume":"66","author":"Legendre","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"13","key":"10.1111\/jth.15773_bb0285","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.15773_bb0290","doi-asserted-by":"crossref","first-page":"100616","DOI":"10.1016\/j.blre.2019.100616","article-title":"Treatment of relapsed multiple myeloma: evidence\u2010based recommendations","volume":"39","author":"Durer","year":"2020","journal-title":"Blood Rev"},{"issue":"2","key":"10.1111\/jth.15773_bb0295","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clml.2016.11.009","article-title":"Incidence and risk of cardiac events in patients with previously treated multiple myeloma versus matched patients without multiple myeloma: an observational, retrospective, cohort study","volume":"17","author":"Kistler","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"10.1111\/jth.15773_bb0300","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1056\/NEJMc053530","article-title":"Lenalidomide and venous thrombosis in multiple myeloma [22]","volume":"354","author":"Knight","year":"2006","journal-title":"N Engl J Med"},{"issue":"3\u20135","key":"10.1111\/jth.15773_bb0305","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jsbmb.2009.05.001","article-title":"Effect of high\u2010dose dexamethasone on endothelial haemostatic gene expression and neutrophil adhesion","volume":"116","author":"Kerachian","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"10.1111\/jth.15773_bb0310","first-page":"797","article-title":"High dose dexamethasone increases circulating P\u2010selectin and von Willebrand factor levels in healthy men","volume":"94","author":"Jilma","year":"2005","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1111\/jth.15773_bb0315","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2042098612452291","article-title":"Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance","volume":"3","author":"Palumbo","year":"2012","journal-title":"Ther Adv Drug Saf"},{"issue":"4","key":"10.1111\/jth.15773_bb0320","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single\u2010agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1111\/jth.15773_bb0325","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjh.16653","article-title":"Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents","volume":"190","author":"Cornell","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1111\/jth.15773_bb0330","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1001\/jamaoncol.2016.3350","article-title":"Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1111\/jth.15773_bb0335","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1182\/blood-2008-02-140434","article-title":"Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping","volume":"112","author":"Johnson","year":"2008","journal-title":"Blood"},{"key":"10.1111\/jth.15773_bb0340","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1111\/jth.15773_bb0345","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1111\/jth.15773_bb0350","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1172\/JCI96400","article-title":"The endothelial cell receptor stabilin\u20102 regulates VWF\u2010FVIII complex half\u2010life and immunogenicity","volume":"128","author":"Swystun","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.15773_bb0355","doi-asserted-by":"crossref","first-page":"104685","DOI":"10.1016\/j.tiv.2019.104685","article-title":"Effects of acrolein in comparison to its prodrug cyclophosphamide on human primary endothelial cells in vitro","volume":"62","author":"Lau","year":"2020","journal-title":"Toxicol Vitr"},{"issue":"12","key":"10.1111\/jth.15773_bb0360","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/s41409-020-0947-9","article-title":"The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium","volume":"55","author":"Martinez\u2010Sanchez","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1111\/jth.15773_bb0365","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens","volume":"32","author":"van Marion","year":"2008","journal-title":"Leuk Res"},{"issue":"2","key":"10.1111\/jth.15773_bb0370","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11239-014-1140-z","article-title":"Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"39","author":"MP","year":"2015","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"10.1111\/jth.15773_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jcm10061169","article-title":"Challenges and advances in managing thrombocytopenic cancer patients","volume":"10","author":"Leader","year":"2021","journal-title":"J Clin Med"},{"issue":"10","key":"10.1111\/jth.15773_bb0380","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"key":"10.1111\/jth.15773_bb0385","doi-asserted-by":"crossref","first-page":"106195","DOI":"10.1016\/j.leukres.2019.106195","article-title":"A review of thrombotic microangiopathies in multiple myeloma","volume":"85","author":"Portuguese","year":"2019","journal-title":"Leuk Res"},{"key":"10.1111\/jth.15773_bb0390","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/bcr-2012-006461","article-title":"Bortezomib\u2010induced thrombotic thrombocytopaenic purpura","volume":"2012","author":"Mehta","year":"2012","journal-title":"BMJ Case Rep."},{"issue":"23","key":"10.1111\/jth.15773_bb0395","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1182\/bloodadvances.2018027532","article-title":"Carfilzomib\u2010induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3\u2010CFHR1 deletion","volume":"2","author":"Portuguese","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"10.1111\/jth.15773_bb0400","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1445-5994.2011.02458.x","article-title":"Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post\u2010bortezomib","volume":"41","author":"Moore","year":"2011","journal-title":"Intern Med J"},{"issue":"3","key":"10.1111\/jth.15773_bb0405","first-page":"53","article-title":"Bortezomib in the upfront treatment of multiple myeloma","volume":"2","author":"San Miguel","year":"2010","journal-title":"Milestones Drug Ther"},{"issue":"11","key":"10.1111\/jth.15773_bb0410","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single\u2010agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"10.1111\/jth.15773_bb0415","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12185-008-0140-1","article-title":"Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma","volume":"88","author":"Morita","year":"2008","journal-title":"Int J Hematol"},{"issue":"4","key":"10.1111\/jth.15773_bb0420","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1002\/ajh.24662","article-title":"Ixazomib\u2010induced thrombotic microangiopathy","volume":"92","author":"Yui","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1111\/jth.15773_bb0425","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1056\/NEJMc1213206","article-title":"ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura","volume":"368","author":"Shortt","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1111\/jth.15773_bb0430","doi-asserted-by":"crossref","first-page":"240","DOI":"10.12691\/ajmcr-7-10-5","article-title":"Late presentation of carfilzomib associated thrombotic microangiopathy","volume":"7","author":"Haddadin","year":"2019","journal-title":"Am J Med Case Rep"},{"key":"10.1111\/jth.15773_bb0435","article-title":"Carfilzomib\u2010induced thrombotic microangiopathy: a case based review","author":"Jindal","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"10.1111\/jth.15773_bb0440","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.bmt.1701830","article-title":"Severe thrombotic microangiopathy: an infrequent complication of bone marrow transplantation","volume":"24","author":"Iacopino","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1111\/jth.15773_bb0445","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1046\/j.1365-2141.2001.02699.x","article-title":"The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation","volume":"113","author":"Fuge","year":"2001","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1111\/jth.15773_bb0450","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11239-013-0893-0","article-title":"Thrombotic thrombocytopenic purpura as initial and major presentation of multiple myeloma","volume":"36","author":"Xiao","year":"2013","journal-title":"J Thromb Thrombolysis"},{"issue":"8","key":"10.1111\/jth.15773_bb0455","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.3324\/haematol.2020.255117","article-title":"Acquired von Willebrand syndrome: focused for hematologists","volume":"105","author":"Franchini","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1111\/jth.15773_bb0460","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)62333-1","article-title":"Acquired von Willebrand disease","volume":"77","author":"Kumar","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"10.1111\/jth.15773_bb0465","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/jth.13317","article-title":"Lenalidomide as a novel treatment for refractory acquired von Willebrand syndrome associated with monoclonal gammopathy","volume":"14","author":"Lavin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1111\/jth.15773_bb0470","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1179\/102453311X12953015767617","article-title":"Acquired von Willebrand syndrome in multiple myeloma","volume":"16","author":"Djunic","year":"2011","journal-title":"Hematology"},{"issue":"3","key":"10.1111\/jth.15773_bb0475","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2141.1993.tb03103.x","article-title":"Expression of GpIb on plasma cells in a patient with monoclonal IgG and acquired von Willebrand disease","volume":"84","author":"Scrobohaci","year":"1993","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1111\/jth.15773_bb0480","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V91.10.3623","article-title":"Clinical significance of inhibitors in acquired von Willebrand syndrome","volume":"91","author":"Mohri","year":"1998","journal-title":"Blood"},{"issue":"2","key":"10.1111\/jth.15773_bb0485","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12185-015-1913-y","article-title":"High coagulation factor VIII and von Willebrand factor in patients with lymphoma and leukemia","volume":"103","author":"Mohren","year":"2016","journal-title":"Int J Hematol"},{"issue":"16","key":"10.1111\/jth.15773_bb0490","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2011-11-388256","article-title":"Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstr\u00f6m macroglobulinemia","volume":"120","author":"Hivert","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1111\/jth.15773_bb0495","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3109\/10428194.2015.1101098","article-title":"Asparaginase\u2010associated toxicity in children with acute lymphoblastic leukemia","volume":"57","author":"Hijiya","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1111\/jth.15773_bb0500","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.54","article-title":"Evaluation of coagulopathy before and during induction chemotherapy for acute lymphoblastic leukaemia, including assessment of global clotting tests","volume":"7","author":"Burley","year":"2017","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1111\/jth.15773_bb0505","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1177\/1078155213508439","article-title":"Prognostic value of plasma levels of thrombomodulin and von Willebrand factor in Egyptian children with acute lymphoblastic leukemia","volume":"20","author":"Hagag","year":"2014","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"10.1111\/jth.15773_bb0510","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000322120","article-title":"Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemia","volume":"125","author":"Hatzipantelis","year":"2011","journal-title":"Acta Haematol"},{"issue":"1","key":"10.1111\/jth.15773_bb0515","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/sj.bjc.6605463","article-title":"Long\u2010term activation of the pro\u2010coagulant response after neoadjuvant chemoradiation and major cancer surgery","volume":"102","author":"Byrne","year":"2010","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1111\/jth.15773_bb0520","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.3748\/wjg.v11.i14.2166","article-title":"Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma","volume":"11","author":"Wang","year":"2005","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1111\/jth.15773_bb0525","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1590\/S0100-879X2001000900004","article-title":"von Willebrand factor antigen levels in plasma of patients with malignant breast disease","volume":"34","author":"R\u00f6hsig","year":"2001","journal-title":"Brazilian J Med Biol Res"},{"key":"10.1111\/jth.15773_bb0530","doi-asserted-by":"crossref","first-page":"e22219","DOI":"10.1002\/jcla.22219","article-title":"Increased von Willebrand factor over decreased ADAMTS\u201013 activity is associated with poor prognosis in patients with advanced non\u2010small\u2010cell lung cancer","volume":"32","author":"Guo","year":"2017","journal-title":"J Clin Lab Anal"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15773","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jth.15773","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622020839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622020839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jth.15773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:35:28Z","timestamp":1761536128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622020839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":105,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1538783622020839"],"URL":"https:\/\/doi.org\/10.1111\/jth.15773","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of VWF\/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.15773","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}]}}